Mean changes from baseline to week 24 in patients with AD assigned to placebo or 15 mg or 20 mg 3 times daily of eptastigmine

ScalePlacebo 15 mg20 mg
*Not significant. AD=Alzheimer's Disease; ADAS-Cog=Alzheimer's Disease Assessment Cognitive Subscale; CIBIC-Plus=Clinician's Interview-Based Impression of Change Plus; IADL=Instrumental Activites of Daily Living Scale.
ADAS-Cog Mean change2.6 1.10.4
Drug-placebo adjusted difference (95% CI)1.6 (0.1 to 3.2)2.3 (0.7 to 3.8)
CIBIC-Plus Mean change4.44.24.0
Drug-placebo adjusted difference (95% CI)0.1 (−0.1 to 0.3)*0.3 (0.1 to 0.5)
IADL Mean change1.20.80.6
Drug-placebo adjusted difference (95% CI)0.4 (−0.1 to 0.9)*0.7 (0.2 to 1.2)